Prescription Drug Promotion from 2001-2014: Data from the US Food and Drug Administration

被引:11
|
作者
Sullivan, Helen W. [1 ]
Aikin, Kathryn J. [1 ]
Chung-Davies, Eunice [1 ]
Wade, Michael [1 ]
机构
[1] US FDA, Silver Spring, MD USA
来源
PLOS ONE | 2016年 / 11卷 / 05期
关键词
CONSUMER; TELEVISION; EXPOSURE;
D O I
10.1371/journal.pone.0155035
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The volume of prescription drug promotion over time is often measured by assessing changes in ad spending. However, this method obscures the fact that some types of advertising are more expensive than others. Another way to measure the changes in prescription drug promotion over time is to assess the number of promotional pieces submitted to the U.S. Food and Drug Administration (FDA). Form FDA 2253 collects information such as the date submitted and the type of material submitted. We analyzed data from Forms FDA 2253 received from 2001-2014. We examined the frequency of submissions by audience (consumer and healthcare professional) and type of promotional material. There was a noted increase in prescription drug promotion submissions across all media in the early 2000s. Although non-Internet promotion submissions have since plateaued, Internet promotion continued to increase. These results can help public health advocates and regulators focus attention and resources.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] THE FOOD-AND-DRUG-ADMINISTRATION RETREATS FROM PATIENT PACKAGE INSERTS FOR PRESCRIPTION DRUGS
    KENDELLEN, RM
    FOOD AND DRUG LAW JOURNAL, 1985, 40 (02): : 172 - 187
  • [32] Current Data on Manganese in Foods and in US Diets from the US Food and Drug Administration's Total Diet Study
    Spungen, Judith H.
    Pouillot, Regis
    Hoffman-Pennesi, Dana
    Briguglio, Stephanie
    Wirtz, Mark
    FASEB JOURNAL, 2016, 30
  • [33] Trends in United States Drug Shortages for Medications Used in Gastroenterology (2001-2014)
    Patel, Jigar
    Fox, Erin R.
    Zocchi, Mark
    Lee, Zone-En
    Mazer-Amirshahi, Maryann
    GASTROENTEROLOGY, 2016, 150 (04) : S633 - S633
  • [34] Evaluation of a US Food and Drug Administration mandate to limit acetaminophen in prescription combination products
    Goldberger, David
    Vearrier, David
    CLINICAL TOXICOLOGY, 2017, 55 (05) : 420 - 420
  • [35] Integrated Drug Reviews at the US Food and Drug Administration Reply
    Doshi, Peter
    Morten, Christopher J.
    Herder, Matthew
    JAMA INTERNAL MEDICINE, 2020, 180 (09) : 1261 - 1262
  • [36] US Food and Drug Administration and Design of Drug Approval Studies
    Woloshin, Steven
    Schwartz, Lisa M.
    Frankel, Brittney
    Faerber, Adrienne
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (20): : 2163 - 2165
  • [37] Promotion of Drugs for Off-label Uses The US Food and Drug Administration at a Crossroads
    Kim, Jeanie
    Kapczynski, Amy
    JAMA INTERNAL MEDICINE, 2017, 177 (02) : 157 - 158
  • [38] Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling
    Gyawali, Bishal
    Darrow, Jonathan J.
    Kesselheim, Aaron S.
    JAMA INTERNAL MEDICINE, 2021, 181 (07) : 897 - 898
  • [39] Characterization of Listeria monocytogenes Recovered from Imported Cheese Contributed to the National PulseNet Database by the US Food and Drug Administration from 2001 to 2008
    Timbo, Babgaleh B.
    Keys, Christine
    Klontz, Karl
    JOURNAL OF FOOD PROTECTION, 2010, 73 (08) : 1511 - 1514
  • [40] Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014
    Pocobelli, Gaia
    Dublin, Sascha
    Bobb, Jennifer F.
    Albertson-Junkans, Ladia
    Andrade, Susan
    Cheetham, T. Craig
    Salgado, Gladys
    Griffin, Marie R.
    Raebel, Marsha A.
    Smith, David
    Li, De-Kun
    Pawloski, Pamala A.
    Toh, Sengwee
    Taylor, Lockwood
    Hua, Wei
    Horn, Pamela
    Trinidad, James P.
    Boudreau, Denise M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (11) : 1541 - 1550